Galectin Therapeutics's total assets for Q1 2025 were $9.53M, a decrease of -45.54% from the previous quarter. GALT total liabilities were $121.79M for the fiscal quarter, a 1.02% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.